Feedback

TOPIC

Psychedelic Research

While the use of psychedelic substances dates back to ancient times, research into their effects and uses was effectively shut down until recently. LSD was first discovered in 1943, and a significant interest developed in the potential psychotherapeutic uses of it and other psychedelic drugs; however, with the rise of the 1960s counterculture movement and its adaptation of psychedelics as an act of rebellion against society, the drugs were deemed dangerous, made illegal, and effectively banned from research. Modern researchers are once again delving into their potential benefits in treating a multitude of issues—from anxiety, depression, and PTSD, to brain injury and even the fear of death associated with terminal cancer.

5 Women in Psychedelics You Should Know About

Badass women making waves in the psychedelic movement, from research to drug policy reform.

Who Will Benefit From Psychedelic Medicine?

These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

The Cost of Exclusion in Psychedelic Research

In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.

How Ecstasy and Psilocybin Are Shaking Up Psychiatry

Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.

A Psychedelic Drug Passes Big Test for PTSD Treatment

In an important step toward medical approval, MDMA, the illegal drug popularly known as Ecstasy or Molly, was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy.

Psychedelic Psychotherapy Is Coming: Who Will Be Included?

A new study finds widespread exclusion of minorities in psychedelic research.

MDMA Lauded as ‘Breakthrough’ Therapy for PTSD Patients

The Food and Drug Administration (FDA) has approved the design of two Phase 3 clinical trials of MDMA for treating PTSD, according to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is funding and leading the clinical trials.

Psychedelics and Race: A Profile of Dr. Monnica T. Williams

The exuberant “renaissance” of studies researching psychedelic-assisted psychotherapy in the past twenty years has not sufficiently included the enrollment of racially diverse participants, a problem that psychedelic science and clinical research shares with mainstream psychiatry

Maps Canada Advances Understanding About Psychedelic Medicines

For the past decade, executive director Mark Haden has been educating physicians on how these molecules could help patients with posttraumatic stress disorder, treatment-resistant depression, and other conditions.

Psychedelics Could Trigger a ‘Paradigm Shift’ in Mental Health Care

A new review of studies finds that LSD, psilocybin, and MDMA hold potential for treating mental illness.

UP NEXT

Psychedelic-Assisted Therapy